Dr Romaana Mir
Professional background
Dr Mir is a Consultant Clinical Oncologist with a special interest in the management of keratinocyte carcinoma, lung, merkel cell carcinoma, and melanoma. She is based at Mount Vernon Cancer Centre and attends King Edward VII Hospital on a tuesday to treat lung cancer with radiotherapy.
Research interests
Dr Mir's research experience is broad having completed two fellowships. She led the international Global Harmonisation Group radiotherapy collaboration (EORTC, IAEA, IROC-NRG, JCOG, RTTQA, TROG) and delivered contouring quality assurance guidelines, which have been incorporated into global clinical practice.
She enjoys co-operative team working and appreciates the importance of collaboration in uniting individuals with differing expertise, ensuring that the highest quality of research is achieved.
Her active research positions include UK Chief Investigator of the EORTC Quality of Life Group Phase I-II Trial, Secretary and Core Expert of the ESTRO Skin and Soft Tissue Focus Group, co-Investigator and radiotherapy lead of the NIHR funded SCC After Trial, and co-Chief Investigator and research supervisor of the TOURIST Trial. In January 2025 she was awarded 2024-2029 N2 level National Clinical Impact Award for her clinical and research work.
Her professional goals are to establish the CONSORT-like international framework for radiotherapy quality assurance reporting and to examine and report the UK implementation of Relatlimab-Nivolumab immunotherapy for advanced melanoma.